Controversies in NMIBC: Guidelines and Beyond
Sam S. Chang, MD, MBA, discusses NMIBC guidelines, best practices, and controversies related to risk-stratification, surveillance, and treatment strategies.
Read MoreSelect Page
Sam S. Chang, MD, MBA, is the Patricia and Rodes Hart Endowed Professor of Urologic Surgery and Oncology and the Chief Surgical Officer of the Vanderbilt Ingram Cancer Center in Nashville, Tennessee. Dr. Chang is a graduate of Princeton University and Vanderbilt University Medical School. He completed his uro-oncology fellowship at Memorial Sloan-Kettering Cancer Center and obtained his MBA at Vanderbilt’s Owen School of Business.
Since his return to Nashville, Dr. Chang has focused on urologic oncology and education and has led efforts in integration of evidence-based medicine in clinical pathways, enhanced national guidelines formulation, and improved urologic cancer staging. He has orchestrated the initiation and expansion of multiple cancer-related treatment protocols at Vanderbilt and elsewhere. Dr. Chang has served as Chair of the Society of Urologic Oncology (SUO) Panel on Hormone Refractory Prostate Cancer, Chair of the American Joint Committee on Cancer (AJCC) GU Staging Task Force, the facilitator and Vice-Chair of the Renal Malignancy Follow-Up AUA Guidelines Panel, the chair of the AUA/ASCO/ASTRO/SUO Guidelines on Nonmetastatic Invasive Bladder Cancer, and Chair of the AUA Prostate Cancer Core Curriculum Committee. He completed his term (2018-2022) as Assistant Secretary of the American Urological Association in charge of International Relations with Europe and the Middle East and served as a member of the initial AUA Task Force on Diversity and Inclusion.
Dr. Chang was a member of the AUA Renal Mass Guidelines as well as the AUA Upper Tract Cancer Guidelines and is a current member of the National Comprehensive Cancer Network (NCCN) Bladder Cancer Panel. His current leadership roles include Secretary of the SUO (2022-2026), Chair of the American Board of Urology Examination Committee (2020-2024), and Trustee for the American Board of Urology (2024-2030).
While maintaining a busy clinical surgical practice, Dr. Chang has authored more than 300 original publications and multiple book chapters. He has also edited several textbooks. For his academic efforts, he received the SUO’s first-ever Distinguished Service Award, aCaPCURE Young Investigator Award, and has been named multiple times as a Journal of Urology’s Best Reviewer. Dr. Chang was named as the 2011 recipient of the American Urologic Association Gold Cystoscope Award and was nominated as Fellow of the Nashville Health Care Council in 2016. His education and mentorship efforts have been recognized with his Department's Best Teaching Faculty Award as well as the Christine Manthos Mentoring Award from the Society of Women in Urology (SWIU).
Posted by Sam S. Chang, MD, MBA | Mar 2023
Sam S. Chang, MD, MBA, discusses NMIBC guidelines, best practices, and controversies related to risk-stratification, surveillance, and treatment strategies.
Read MorePosted by Sam S. Chang, MD, MBA | Sep 2018
Sam S. Chang, MD, MBA, and Michael S. Cookson, MD, led the “Next Generation Developments in Bladder Cancer” session at the Future Directions in Urology Symposium (FDUS) 2018. These consensus statements represent a comprehensive analysis of current issues, challenges, and advancements in urology from a panel of international experts.
Read MorePosted by Sam S. Chang, MD, MBA | Feb 2018
Sam Chang, MD, MBA, who has served as chair of the American Urological Association (AUA) guidelines panel for non-muscle invasive bladder cancer (NMIBC) and muscle invasive bladder cancer (MIBC), provides an overview of updated non-metastatic MIBC treatment guidelines, including a comprehensive treatment algorithm. He also discusses directions of future research for the disease.
Read MorePosted by Sam S. Chang, MD, MBA | Feb 2018
Sam Chang, MD, MBA, delineates the benefits and shortcomings of both robotic and open cystectomy, specifically in terms of morbidity, compilation, and recurrence rates for patients, and the learning curve associated with each method for clinicians. He also discusses how the financial cost of robotic surgery factors into this comparison.
Read MorePosted by Sam S. Chang, MD, MBA | May 2017
Dr. Sam S. Chang presented “Robotic Cystectomy Versus Open Cystectomy: Do We Really Need to...
Read More